DRUG · Unmapped registry intervention
AMG 102 and erlotinib
Find medicine records ·
Find other trials using this name
Clinical trial
AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
NCT01233687
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedAMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Carcinoma, Non-Small-Cell Lungunresolved
Interventions
Sponsors & collaborators
Ahmad Tarhinilead sponsor
Amgencollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01233687 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.